Nonadherence to statins: individualized intervention strategies outside the pill box.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Evolocumab 1 endocrinologydiseasesdrugs
atorvastatin 5 endocrinologydiseasesdrugs
diabetes mellitus 2 endocrinologydiseases
ezetimibe 5 endocrinologydiseasesdrugs
rosuvastatin 2 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Evolocumab 12863 in Statin Intolerant Subjects 3) trial in patients with documented clinical statin intolerance.[45] Evolocumab resulted in significantly greater reduction in LDL-C after 24 weeks compared with ezetimibe. Subcutaneously
atorvastatin 2962 years.[10] Medical advances in the past decade, particularly the introduction of potent statins such as atorvastatin and rosuvastatin, have made achieving lower LDL-C levels within reach for most individuals at risk of
atorvastatin 14888 prescription of higher doses of other statins. No difference has been identified in systemic exposure with atorvastatin between Asians and Caucasians.[55] Atorvastatin (10–80 mg) has been found to be equally efficacious
atorvastatin 15115 Asian and Western populations.[56],[57] Therefore, there is no regulatory warning about the dose of atorvastatin in Asians.[57]The nocebo responseIn patients presenting with only mild myalgia, a nocebo response should
atorvastatin 15565 how placebo affects outcome in a positive way.[60]In a recent study by Gupta et al, AEs reported with atorvastatin therapy during a blinded, randomized, placebo- controlled phase were compared with those during an unblinded,
atorvastatin 15741 were compared with those during an unblinded, nonrandomized phase when open-labeled treatment with atorvastatin was continued.[61] The study found an excess rate of muscle-related AEs when patients and their doctors
ezetimibe 12331 recommendations on the use of non-statins. Addition of a non-statin cholesterol-lowering therapy (either ezetimibe or a proprotein convertase subtilisin/kexin 9 [PCSK9] inhibitor) is recommended for high-risk patients
ezetimibe 12541 patients who are statin intolerant. Bile acid sequestrants are recommended only in patients intolerant to ezetimibe .[41]The lipid-lowering capability of the two recommended non-statin medications, ezetimibe and evolocumab
ezetimibe 12632 intolerant to ezetimibe.[41]The lipid-lowering capability of the two recommended non-statin medications, ezetimibe and evolocumab (a PCSK9 inhibitor), was compared in the GAUSS-3 (Goal Achievement After Utilizing an
ezetimibe 12956 intolerance.[45] Evolocumab resulted in significantly greater reduction in LDL-C after 24 weeks compared with ezetimibe . Subcutaneously administered PCSK9 inhibitors have demonstrated marked reduction in LDL-C both as a
ezetimibe 13115 have demonstrated marked reduction in LDL-C both as a monotherapy and when combined with statin and/or ezetimibe therapy.[46] National Lipid Association 2017 Expert Panel on treatment with PCSK9 inhibitors recommend
rosuvastatin 2979 advances in the past decade, particularly the introduction of potent statins such as atorvastatin and rosuvastatin , have made achieving lower LDL-C levels within reach for most individuals at risk of CVD.[11] However,
rosuvastatin 14516 than Western populations.[49] Several studies have demonstrated an increased systemic exposure with rosuvastatin in Asians.[50]–[52] Data indicate that polymorphisms in the SLCO1B1 and ABCG2 genes contribute to
Select Disease Character Offset Disease Term Instance
diabetes mellitus 7320 their use. Serious adverse events (AEs) associated with statin therapy include myopathy, new-onset diabetes mellitus (NODM), and hemorrhagic stroke.[28] Five cases of myopathy may be seen when 10,000 patients are treated
diabetes mellitus 9262 for health providers to determine if an individual is truly intolerant to statins or not.New-onset diabetes mellitus There is a reported 10%–12% increase in NODM among patients receiving statins; this risk increases

You must be authorized to submit a review.